NxStage Medical, Inc. (NASDAQ:NXTM) SVP Matthew W. Towse sold 4,300 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $21.36, for a total value of $91,848.00. Following the completion of the transaction, the senior vice president now directly owns 29,637 shares in the company, valued at $633,046.32. The sale was disclosed in a legal filing with the SEC, which is available through this link.
NxStage Medical, Inc. (NASDAQ:NXTM) traded up 2.63% on Thursday, reaching $22.64. 230,911 shares of the company traded hands. NxStage Medical, Inc. has a 52-week low of $18.28 and a 52-week high of $30.80. The stock has a 50-day moving average of $25.76 and a 200 day moving average of $26.52. The company’s market capitalization is $1.49 billion.
NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Tuesday, May 9th. The medical device company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. NxStage Medical had a negative net margin of 1.61% and a negative return on equity of 2.97%. The firm had revenue of $96.83 million for the quarter, compared to analyst estimates of $95.31 million. During the same quarter last year, the business posted ($0.02) earnings per share. The company’s quarterly revenue was up 8.5% on a year-over-year basis. On average, equities analysts forecast that NxStage Medical, Inc. will post ($0.03) EPS for the current year.
Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in shares of NxStage Medical during the first quarter worth $140,000. Ameritas Investment Partners Inc. bought a new stake in shares of NxStage Medical during the first quarter worth $148,000. Fortaleza Asset Management Inc. raised its stake in shares of NxStage Medical by 2.5% in the fourth quarter. Fortaleza Asset Management Inc. now owns 8,055 shares of the medical device company’s stock worth $211,000 after buying an additional 195 shares in the last quarter. Menta Capital LLC bought a new stake in shares of NxStage Medical during the first quarter worth $212,000. Finally, Jane Street Group LLC bought a new stake in shares of NxStage Medical during the first quarter worth $213,000. Hedge funds and other institutional investors own 97.26% of the company’s stock.
NXTM has been the topic of several recent analyst reports. Jefferies Group LLC boosted their target price on NxStage Medical to $38.00 and gave the stock a “buy” rating in a report on Monday, February 6th. Northland Securities reissued a “buy” rating and issued a $35.00 target price on shares of NxStage Medical in a report on Monday, April 3rd. Canaccord Genuity reissued a “buy” rating and issued a $32.00 target price on shares of NxStage Medical in a report on Monday, May 8th. Finally, BTIG Research reissued a “buy” rating and issued a $27.00 target price on shares of NxStage Medical in a report on Wednesday, May 10th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $28.67.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.